NAVIDEA BIOPHARMACEUTICALS, INC. Warrant To Purchase Common StockWarrant Agreement • July 20th, 2022 • Navidea Biopharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • New York
THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (Eastern Time) on _____, 20271 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Navidea Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant shall initially be issued and maintained in the form of a security held in book-entry form and the Depository Trust Company or its nominee (“DTC”) shall initially be the sole registered holder of this Warrant, subject to Holde
WARRANT AGENCY AGREEMENTWarrant Agency Agreement • July 20th, 2022 • Navidea Biopharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • New York
WARRANT AGENCY AGREEMENT, dated as of July , 2022 (“Agreement”), by and between Navidea Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (the “Warrant Agent”).
